Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23240707 | 0.86 | ATP1A1 (0.47) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL2342912 | 0.84 | ALDH1A1 (0.48) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL31193433 | 0.81 | MAOA (0.64) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL6570481 | 0.81 | MAOA (0.64) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL12608741 | 0.81 | MAOA (0.68) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL6354852 | 0.79 | MAOA (0.63) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL5782106 | 0.78 | MAOA (0.64) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL13005222 | 0.78 | MAOA (0.64) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL29547534 | 0.78 | MAOA (0.64) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL3267918 | 0.78 | MAOA (0.64) | MAOAKDM4EALDH1A1GLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896467-B1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-01 | — | — | EP | disclosed |
| EP-1896467-B1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-01 | — | — | EP | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| EP-1896467-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138528-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
| EP-0457721-A1 | NIR-absorbant dyes | CIBA-GEIGY AG (CH) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | MAOA 555/4885KDM4E 2206/4885ALDH1A1 927/4885 |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | MAOA 555/4885KDM4E 2206/4885ALDH1A1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.